Chronic Lymphocytic Leukemia
Researchers identified a single heterozygous nucleotide variant that confers resistance to venetoclax, and it's a mutation that may be detected years before clinical relapse occurs.
Three-year outcomes reveal a new standard of care in patients with CLL who are younger than 70.
Although PFS with ibrutinib-containing regimens was favorable compared with bendamustine rituximab, overall survival was not different across the study arms.
Although CAR-T alone has shown utility in CLL, evidence suggests the addition of ibrutinib could improve the durability of remission.
Favorable data on liso-cel bolsters its chances of moving into further stages of development, provided complete responses remain durable.
Rod A. Humerickhouse, MD, PhD, discusses updated findings at the ASH 2018 meeting.
Cell surface antigen Siglec-6 was broadly expressed in chronic lymphocytic leukemia after transplantation, suggesting a new potential drug target.
Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.
There are several novel agents, such as ibrutinib, idelalisib, and venetoclax, that could improve outcomes in CLL patients with 17p deletions and TP53 mutations.
AID is a mutator enzyme that plays an essential role for somatic hypermutation and class switch recombination during effective adaptive immune responses.
By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.
Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.
A regimen showed favorable minimal residual disease negativity in patients with high-risk CLL, allowing many to pursue transplantation.
Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.
Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.
Immune changes in the tumor microenvironment were associated with clinical response to lenalidomide in patients with chronic lymphocytic leukemia.
High comorbidity burden was associated with worse survival outcomes in patients with chronic lymphocytic leukemia who were treated with ibrutinib.
A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.
Duvelisib improved PFS by more than 3 months compared with ofatumumab, the current standard of care, in relapsed or refractory CLL and SLL.
In patients with chronic lymphocytic leukemia, a lower ibrutinib dose appears to confer sufficient biological activity, but further study is needed.
Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?October 04, 2018
In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.
Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.
Investigators found that dosing of IgRT in CLL at target levels higher than conventional parameters may offer a therapeutic benefit.
Transplant-naive patients were more likely to achieve an optimal drug response — but were also more prone to severe cytokine release syndrome and neurotoxicity.
More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.
There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.
Researchers hypothesized that a combination bispecific mAb in B-cell malignancies could offer a treatment option superior to existing monospecific mAbs.
The feasibility of lenalidomide in combination therapy for chronic lymphocytic leukemia is in question.
Ibrutinib May Be Effective in Patients With Chronic Lymphocytic Leukemia Who Were Excluded from Clinical TrialsAugust 30, 2018
The RESONATE-2 trial excluded certain patients with chronic lymphocytic leukemia, leaving the efficacy and tolerability of ibrutinib in this population unknown.
Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified
- Gly101Val Mutation Directly Causes Resistance to Venetoclax
- Can Treatments for Childhood ALL Alter the Gut Microbiome?